Month: December 2022

Tang, Fan published the artcileThe dissipation of cyazofamid and its main metabolite in soil response oppositely to biochar application, Formula: C11H8ClN3, the publication is Chemosphere (2019), 26-35, database is CAplus and MEDLINE.

Biochars derived from rice straw (RS), corn straw (CS), chicken manure (CM) and tire rubber (TR) were applied to soil to investigate their effects on the dissipation of cyazofamid and its metabolite CCIM (4-chloro-5-p-tolylimidazole-2-carbonitrile), with high acute toxicity compared to cyazofamid. The enhancement of cyazofamid dissipation followed the order of CS > RS > CM, whereas TR depressed the cyazofamid dissipation. Adsorption, hydrolysis and microbial degradation were all involved in cyazofamid dissipation. CM and CS enhanced the contribution of biodegradation to cyazofamid dissipation, which might be related with the shifted microbial community. More importantly, CCIM residual was drastically increased by 8-15 times after biochar application, regardless of biochar type. In total, this study shed light on the issue of build-up of metabolites in biochar-amended soil, especially for metabolites having higher toxicities than parent compounds, providing new insights into potential risk of biochar application for soil remediation.

Chemosphere published new progress about 120118-14-1. 120118-14-1 belongs to imidazoles-derivatives, auxiliary class Imidazole,Chloride,Nitrile,Benzene, name is 4-Chloro-5-(p-tolyl)-1H-imidazole-2-carbonitrile, and the molecular formula is C17H37NO3, Formula: C11H8ClN3.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Chen, Jiuyan published the artcileThe mechanisms involved into the inhibitory effects of ionic liquids chemistry on adsorption performance of ciprofloxacin onto inorganic minerals, Recommanded Product: 3-Butyl-1-methyl-1H-imidazol-3-ium chloride, the publication is Colloids and Surfaces, A: Physicochemical and Engineering Aspects (2022), 129422, database is CAplus.

The ionic liquids (ILs) can influence the adsorption of antibiotics on minerals but there was ambiguity about mechanisms. Herein, we demonstrated the adsorption characteristics of ciprofloxacin (CIP) onto ferrihydrite and montmorillonite by various soluble ILs. Five imidazolium-based ILs with different alkyl chain lengths ([C₂mim]Cl, [C₄mim]Cl, [C₆mim]Cl) and counteranions ([C₄mim][TOS] and [C₄mim][PF₆]) were employed. The results validated that ILs could suppress CIP adsorption on both minerals due to the adsorption site competition between cations and CIP mols., steric hindrance induced by long alkyl chains of ILs, and electrostatic interaction. Interestingly, the adsorption-inhibition effects of ILs were almost unchanged with the lengthening alkyl chain for ferrihydrite, which were ascribed to the comparable adsorption capacities of the three ILs on ferrihydrite. Whereas, the effects of ILs on CIP adsorption onto montmorillonite followed the order of [C₆mim]Cl > [C₄mim]Cl > [C₂mim]Cl owing to the adsorption site competition and steric hindrance effects on the ILs increased with the lengthening alkyl chain. Furthermore, the inhibitory effects of ILs on CIP adsorption onto both studied minerals were also dependent on the counteranions (kept the same cation ([C₄mim]+)) and in the following order of [C₄mim][PF₆] > [C₄mim][TOS] > [C₄mim]Cl, which was mainly ascribed to the differences of anions in the ion sizes and the binding affinities to minerals. Addnl., the extent of the inhibitory impact of [C₄mim][TOS] on CIP adsorption onto ferrihydrite declined with increasing solution pH from 5.0 to 9.0, which was attributed to the amounts of adsorbed [TOS]^– declined with increasing pH. Contrarily, for montmorillonite, the extent increased with increasing pH, owing to increase in adsorption site competition and steric effect at higher pH conditions. Our findings emphasize the significance of emerging contaminants in understanding the antibiotic environmental behavior in eco-environmental systems.

Colloids and Surfaces, A: Physicochemical and Engineering Aspects published new progress about 79917-90-1. 79917-90-1 belongs to imidazoles-derivatives, auxiliary class Ionic Liquid,Ionic Liquid, name is 3-Butyl-1-methyl-1H-imidazol-3-ium chloride, and the molecular formula is C8H15ClN2, Recommanded Product: 3-Butyl-1-methyl-1H-imidazol-3-ium chloride.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Li, Jiang-Fei published the artcileConstruction 7-membered ring via Ni-Al bimetal-enabled C-H cyclization for synthesis of tricyclic imidazoles, Safety of 1,3-Bis(2,6-diisopropylphenyl)-4,5-dihydro-1H-imidazol-3-ium chloride, the publication is Nature Communications (2021), 12(1), 3070, database is CAplus and MEDLINE.

A direct construction of 7-membered rings via Ni-Al co-catalyzed unreactive C7-H cyclization of benzoimidazoles with alkenes, providing a series of tricyclic imidazoles such as I [R = Me, 2-FC₆H₄, BnO(CH₂)₂, etc.; R¹ = CF₃, 3-pyridyl, Bn, etc.; R² = H, 4-t-Bu, 4,5-F₂, etc.] in 40-98% yield and with up to 95:5 er was reported.

Nature Communications published new progress about 258278-25-0. 258278-25-0 belongs to imidazoles-derivatives, auxiliary class Achiral NHCs Ligands, name is 1,3-Bis(2,6-diisopropylphenyl)-4,5-dihydro-1H-imidazol-3-ium chloride, and the molecular formula is C27H39ClN2, Safety of 1,3-Bis(2,6-diisopropylphenyl)-4,5-dihydro-1H-imidazol-3-ium chloride.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Yang, Ze-Kun published the artcileCross-coupling polycondensation via C-O or C-N bond cleavage, Safety of 1,3-Bis(2,6-diisopropylphenyl)-4,5-dihydro-1H-imidazol-3-ium chloride, the publication is Nature Communications (2018), 9(1), 1-7, database is CAplus and MEDLINE.

π-Conjugated polymers are widely used in optoelectronics for fabrication of organic photovoltaic devices, organic light-emitting diodes, organic field effect transistors, and so on. Here we describe the protocol for polycondensation of bifunctional aryl ethers or aryl ammonium salts with aromatic dimetallic compounds through cleavage of inert C-O/C-N bonds. This reaction proceeds smoothly in the presence of com. available Ni/Pd catalyst under mild conditions, affording the corresponding π-conjugated polymers with high mol. weight The method is applicable to monomers that are unreactive in other currently employed polymerization procedures, and opens up the possibility of transforming a range of naturally abundant chems. into useful functional compounds/polymers.

Nature Communications published new progress about 258278-25-0. 258278-25-0 belongs to imidazoles-derivatives, auxiliary class Achiral NHCs Ligands, name is 1,3-Bis(2,6-diisopropylphenyl)-4,5-dihydro-1H-imidazol-3-ium chloride, and the molecular formula is C11H21BF4N2O2, Safety of 1,3-Bis(2,6-diisopropylphenyl)-4,5-dihydro-1H-imidazol-3-ium chloride.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Zhu, Ling-Ling published the artcilePoor awareness of preventing aspirin-induced gastrointestinal injury with combined protective medications, Quality Control of 161796-78-7, the publication is World Journal of Gastroenterology (2012), 18(24), 3167-3172, database is CAplus and MEDLINE.

Aim: To investigate prescribing pattern in low-dose aspirin users and physician awareness of preventing aspirin-induced gastrointestinal (GI) injury with combined protective medications. Methods: A retrospective drug utilization study was conducted in the 2nd Affiliated Hospital, School of Medicine, Zhejiang University. The hospital has 2300 beds and 2.5 million outpatient visits annually. Data mining was performed on all aspirin prescriptions for outpatients and emergency patients admitted in 2011. Concomitant use of proton-pump inhibitors (PPIs), histamine 2-receptor antagonists (H2RA) and muco-protective drugs (MPs) were analyzed. A defined daily dose (DDD) methodol. was applied to each MP. A further investigation was performed in aspirin users on combination use of GI injurious medicines [non-steoid anti-inflammatory drugs (NSAIDs), corticosteroids and clopidogrel and warfarin] or intestinal protective drugs (misoprostol, rebamipide, teprenone and gefarnate). Data of major bleeding episodes were derived from medical records and adverse drug reaction monitoring records. The annual incidence of major GI bleeding due to low-dose aspirin was estimated for outpatients. Results: Prescriptions for aspirin users receiving PPIs, H2RA and MPs (n = 1039) accounted for only 3.46% of total aspirin prescriptions (n = 30 015). The ratios of coadministration of aspirin/PPI, aspirin/H2RA, aspirin/MP and aspirin/PPI/MP to the total aspirin prescriptions were 2.82%, 0.12%, 0.40% and 0.12%, resp. No statistically significant difference was observed in age between patients not receiving any GI protective medications and patients receiving PPIs, H2RA or MPs. The combined medication of aspirin and PPI was used more frequently than that of aspirin and MPs (2.82% vs. 0.40%, P < 0.05) and aspirin/H2RA (2.82% vs. 0.12%, P < 0.05). The values of DDDs of MPs in descending order were as follows: gefarnate, hydrotalcite > teprenone > sucralfate oral suspension > -glutamine and sodium gualenate granules > rebamipide > sucralfate chewable tablets. The ratio of MP plus aspirin prescriptions to the total MP prescriptions was as follows: rebamipide (0.47%), teprenone (0.91%), -glutamine and sodium gualenate granules (0.92%), gefarnate (0.31%), hydrotalcite (1.00%) and sucralfate oral suspension (0.13%). Percentages of prescriptions containing aspirin and intestinal protective drugs among the total aspirin prescriptions were: rebamipide (0.010%), PPI/rebamipide (0.027%), teprenone (0.11%), PPI/teprenone (0.037%), gefarnate (0.017%), and PPI/gefarnate (0.013%). No prescriptions were found containing coadministration of aspirin and other NSAIDs. Among the 3196 prescriptions containing aspirin/clopidogrel, 3088 (96.6%) prescriptions did not contain any GI protective medicines. Of the 389 prescriptions containing aspirin/corticosteroids, 236 (60.7%) contained no GI protective medicines. None of the prescriptions using aspirin/warfarin (n = 22) contained GI protective medicines. Thirty-five patients were admitted to this hospital in 2011 because of acute hemorrhage of upper digestive tract induced by low-dose aspirin. The annual incidence rates of major GI bleeding were estimated at 0.25% for outpatients taking aspirin and 0.5% for outpatients taking aspirin/warfarin, resp. Conclusion: The prescribing pattern of low-dose aspirin revealed a poor awareness of preventing GI injury with combined protective medications. Actions should be taken to address this issue.

World Journal of Gastroenterology published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C15H15OP, Quality Control of 161796-78-7.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Zhang, C. published the artcileEfficient synthesis and biological activity of novel indole derivatives as VEGFR-2 tyrosine kinase inhibitors, SDS of cas: 4760-35-4, the publication is Russian Journal of General Chemistry (2017), 87(12), 3006-3016, database is CAplus.

Series of novel indole derivatives, e.g. I were synthesized as potent inhibitors for the vascular endothelial growth factor receptor 2 (VEGFR-2) tyrosine kinase. Among those, compound I demonstrated the highest growth inhibition rate of 66.7% against the VEGFR-2 tyrosine kinase at 10 μM which indicates that indole-benzothiazole might be the favorable structure. The binding mode of compound I with VEGFR-2 tyrosine kinase was evaluated by mol. docking.

Russian Journal of General Chemistry published new progress about 4760-35-4. 4760-35-4 belongs to imidazoles-derivatives, auxiliary class Chloride,Benzimidazole, name is 2-(Chloromethyl)-1-methyl-1H-benzo[d]imidazole, and the molecular formula is C3H9ClOS, SDS of cas: 4760-35-4.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Ning, Binke published the artcileSynthesis, characterization and crystal structure of cyazofamid, Related Products of imidazoles-derivatives, the publication is Yingyong Huagong (2010), 39(9), 1351-1354, database is CAplus.

Fungicide cyazofamid and its isomer were synthesized and their structures were established by IR, elemental anal. and ¹H NMR. The single crystal structure of cyazofamid was determined by X-ray diffraction anal. The crystal belongs to monoclinic system, space group P2(1)/n, cell parameters: a=0.68045(18) nm, b=1.3363(4) nm, c=1.6427(4) nm, α=90°, β=93.048(4)°, γ=90°, V=1.4916(7) nm³, Z=4, Dc=1.446 mg/m³, μ=0.405 mm^-1, F(000)=672.

Yingyong Huagong published new progress about 120118-14-1. 120118-14-1 belongs to imidazoles-derivatives, auxiliary class Imidazole,Chloride,Nitrile,Benzene, name is 4-Chloro-5-(p-tolyl)-1H-imidazole-2-carbonitrile, and the molecular formula is C11H8ClN3, Related Products of imidazoles-derivatives.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Liu, Xiaojie published the artcileNi-Catalyzed Deoxygenative Borylation of Phenols Via O-Phenyl-uronium Activation, SDS of cas: 258278-25-0, the publication is ACS Catalysis (2022), 12(15), 8904-8910, database is CAplus.

Herein, we report an efficient method for the Ni-catalyzed deoxygenative borylation of unprotected phenols and also demonstrate that this Ni-catalyzed phenolic C(sp²)-O transformation is applicable to the Suzuki-Miyaura-type and Heck-type cross-couplings of phenols. Investigations on the reaction intermediate have revealed that the achievement of general, mild deoxygenative cross-coupling reactions of phenols is ascribed to the conversion of phenols into the unusual O-phenyl-uroniums that feature active phenolic C(sp²)-O bonds. The Ni-complex intermediate resulting from an oxidative addition of a phenolic C(sp²)-O bond to monophosphine-supported Ni(0) catalyst was characterized and confirmed to be (PCy₃)₂Ni(Ar)(F) complex, offering exptl. evidence for the generally proposed C(sp²)-O oxidative addition step.

ACS Catalysis published new progress about 258278-25-0. 258278-25-0 belongs to imidazoles-derivatives, auxiliary class Achiral NHCs Ligands, name is 1,3-Bis(2,6-diisopropylphenyl)-4,5-dihydro-1H-imidazol-3-ium chloride, and the molecular formula is C27H39ClN2, SDS of cas: 258278-25-0.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Zhong, Renyuan published the artcileHighly Efficient and Ambient-Temperature Synthesis of Benzimidazoles via Co(III)/Co(II)-Mediated Redox Catalysis, Formula: C19H14N2, the publication is Catalysts (2022), 12(1), 59, database is CAplus.

An efficient method for ambient-temperature synthesis of a variety of 2-substituted and 1,2-disubstituted benzimidazoles from aldehyde and phenylenediamine substrates has been developed by utilizing Co(III)/Co(II)-mediated redox catalysis. The combination of only 1 mol% of Co(acac)₂ and stoichiometric amount of hydrogen peroxide provides a fast, green, and mild access to a diversity of benzimidazoles under solvent-free conditions.

Catalysts published new progress about 2622-67-5. 2622-67-5 belongs to imidazoles-derivatives, auxiliary class Benzimidazole,Benzene,Benzimidazole, name is 1,2-Diphenyl-1H-benzo[d]imidazole, and the molecular formula is C3H3Br2ClO, Formula: C19H14N2.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Li, Qi published the artcileDiscovery and Biological Evaluation of a Novel Highly Potent Selective Butyrylcholinsterase Inhibitor, Recommanded Product: 4-(1H-Benzo[d]imidazol-2-yl)-1,2,5-oxadiazol-3-amine, the publication is Journal of Medicinal Chemistry (2020), 63(17), 10030-10044, database is CAplus and MEDLINE.

To discover novel BChE inhibitors, a hierarchical virtual screening protocol followed by biochem. evaluation was applied. The most potent compound 8012-9656(I) (eqBChE IC₅₀ = 0.18 ± 0.03 μM, hBChE IC₅₀ = 0.32 ± 0.07 μM) was purchased and synthesized. It inhibited BChE in a noncompetitive manner and could occupy the binding pocket forming diverse interactions with the target. 8012-9656 was proven to be safe in vivo and in vitro and showed comparable performance in ameliorating the scopolamine-induced cognition impairment to tacrine. Addnl., treatment with 8012-9656 could almost entirely recover the Aβ_1-42 (icv)-impaired cognitive function to the normal level and showed better behavioral performance than donepezil. The evaluation of the Aβ_1-42 total amount confirmed its anti-amyloidogenic profile. Moreover, 8012-9656 possessed blood-brain barrier (BBB) penetrating ability, a long T_1/2, and low intrinsic clearance. Hence, the novel potential BChE inhibitor 8012-9656 can be considered as a promising lead compound for further investigation of anti-AD agents.

Journal of Medicinal Chemistry published new progress about 332026-86-5. 332026-86-5 belongs to imidazoles-derivatives, auxiliary class Oxadiazole,Amine,Benzimidazole, name is 4-(1H-Benzo[d]imidazol-2-yl)-1,2,5-oxadiazol-3-amine, and the molecular formula is C9H7N5O, Recommanded Product: 4-(1H-Benzo[d]imidazol-2-yl)-1,2,5-oxadiazol-3-amine.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem